Page results
-
Irreversible Electroporation for Prostate Cancer (IRE or Nanoknife™) patient information page.
-
HTD Outpatients offers a wide range of clinics for Chagas disease, Infectious diseases, Leishmaniasis, Leprosy , Malaria , Microbiology, Neglected tropical diseases, Parasitology
-
Information about having a gadolinium-based contrast agent for MRI examinations while breastfeeding.
-
Patient information leaflet for Functional Electrical Stimulation (FES) Clinic
-
This information has been written to help you now that your radiotherapy treatment is finishing.
-
The fertility laboratory provides three main services. Semen analysis to test fertility, storage of semen samples and processing of semen samples for IUI treatments.
-
This page is for patients who are having stereotactic ablative body radiotherapy (SABR) for lung cancer.
-
Perinatal Mental Health Service in Partnership with North London Partners Specialist Perinatal Mental Health Service
-
Antenatal care and screening is an essential part of maternity care for all women. We provide state-of-the-art ultrasound screening, specialist obstetric and midwifery clinics.
-
This page has been written for patients who are having a course of superficial radiotherapy for a skin tumour (such as a basal cell carcinoma or squamous cell carcinoma), or some other skin condition.
File results
-
FOI/2022/0530 - Neonatal sepsis guidance
-
FOI/2022/0531 - Operating theatres in Trust
-
FOI/2022/0533 - Pathology service carrying out PCR testing for SARS-CoV2
-
FOI/2022/0539 - Pharmacological choices made for patients undergoing joint replacement surgery
-
FOI/2022/0557 - Patients treated with Visudyne (verteporfin)
-
FOI/2022/0563 - Ambulatory cardiac monitoring
-
FOI/2022/0544 - Wards/ departments that provide services to 0-17 year-olds
-
FOI/2022/0545 - Criteria used in determining acceptance of GP referrals for osteoporosis treatment, and for priorisation of osteoporosis appointments
-
FOI/2022/0546 - Metastatic Cholangiocarcinoma (CCA) or Acute myeloid leukaemia
-
FOI/2022/0548 - Biologic and biosimilar products within Rheumatology